Analyzing...
Loading company...
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 1,645 full-time employees. The company went IPO on 2016-05-09. The firm has diagnostic chains that conduct a range of medical diagnostic tests and profiles of tests that is focused on early detection and management of health disorders and diseases. The firm's segments include Diagnostic Testing Services, Imaging Services and Others. The Diagnostic Testing Services segment includes diagnostic and testing services, selling of consumables used for collection and promotion of pathology. The Imaging Services includes diagnostic and imaging services, selling of radio-pharmaceutical, selling of consumables for reporting. The Others segment include the sale of testing equipment and consumables, and selling of glucometer and glucostrips under the brand, Sugarscan. The firm has a centralized fully automated diagnostic testing laboratory, regional processing laboratories, a medical cyclotron facility and PET-CT facilities across India.
No significant concerns identified
Nothing flagged for monitoring
“Services business in Healthcare — Hospitals & Diagnostics.”
₹829 Cr service revenue.
Employee costs at 16.7% of revenue — primary cost driver.
“I have consistently been guiding that our long term growth rate will be mid teens.”
“consolidated level, we delivered revenue growth of 18% year on year, primarily driven by our Pathology business, which grew 20% year on year.”
“growth rate point of view is definitely achievable, but it will come at a cost.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 27.9%▲ | 9.0% |
| ROCE | 33.6%▲ | 10.4% |
| Net Margin | 19.3%▲ | 8.5% |
| EBITDA Margin | 32.3%▲ | 20.6% |
| Debt To Equity | 0.00x▼ | 0.16x |
| Rev Growth 3yr | 16.5%▲ | 14.4% |
| EPS Growth 3yr | 36.1%▲ | 9.9% |
| Employee Cost Ratio | 16.70x | - |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹829 Cr +20.6% | ₹687 Cr +20.2% | ₹572 Cr +8.6% | ₹527 Cr -10.6% | ₹589 Cr +19.1% | ₹495 Cr +14.2% | ₹433 Cr +7.5% | ₹403 Cr |
| Other Income | ₹17 Cr +14.6% | ₹15 Cr +58.3% | ₹9 Cr +11.3% | ₹8 Cr -71.2% | ₹29 Cr +135.3% | ₹12 Cr +60.8% | ₹8 Cr -22.3% | ₹10 Cr |
| Total Income | ₹846 Cr +20.5% | ₹702 Cr +20.8% | ₹581 Cr +8.6% | ₹535 Cr -13.4% | ₹618 Cr +21.9% | ₹507 Cr +15.0% | ₹441 Cr +6.8% | ₹413 Cr |
| COGS | ₹220 Cr +14.9% | ₹191 Cr +14.6% | ₹167 Cr +2.1% | ₹163 Cr -3.8% | ₹170 Cr +3.5% | ₹164 Cr +40.0% | ₹117 Cr +5.9% | ₹111 Cr |
| ₹628 Cr +13.2% | ₹555 Cr +14.3% | ₹486 Cr +8.5% | ₹448 Cr +14.7% | ₹390 Cr +10.1% | ₹355 Cr +20.4% | ₹294 Cr +6.9% | ₹275 Cr | |
| Profit Before Tax | ₹211 Cr +44.0% | ₹147 Cr +53.7% | ₹96 Cr +9.4% | ₹87 Cr -61.6% | ₹228 Cr +49.4% | ₹153 Cr +9.0% | ₹140 Cr +1.8% | ₹137 Cr |
| Exceptional Items | (₹6 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹7 Cr) | ₹0.00 Cr |
| ₹50 Cr -8.5% | ₹55 Cr +106.5% | ₹26 Cr +9.3% | ₹24 Cr -53.0% | ₹52 Cr +31.2% | ₹39 Cr -24.4% | ₹52 Cr -1.7% | ₹53 Cr | |
| Net Profit | ₹163 Cr +79.4% | ₹91 Cr +30.6% | ₹69 Cr +8.0% | ₹64 Cr -63.5% | ₹176 Cr +55.7% | ₹113 Cr +28.0% | ₹88 Cr +3.8% | ₹85 Cr |
| Profit (Owners) | ₹163 Cr +78.2% | ₹92 Cr +29.3% | ₹71 Cr +9.7% | ₹64 Cr -63.4% | ₹176 Cr +55.7% | ₹113 Cr +28.0% | ₹88 Cr +3.8% | ₹85 Cr |
| Minority Interest | (₹0.19 Cr) +74.5% | (₹0.76 Cr) +40.2% | (₹1 Cr) -876.9% | (₹0.13 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | ₹0.38 Cr ↑ Recovery | (₹0.77 Cr) ↓ Decline | ₹0.29 Cr -81.0% | ₹2 Cr ↑ Recovery | (₹0.08 Cr) +94.2% | (₹1 Cr) ↓ Decline | ₹0.12 Cr +9.1% | ₹0.11 Cr |
| EPS | ₹10.25 | ₹5.76 | ₹4.45 | ₹4.06 | ₹11.10 | ₹7.13 | ₹5.58 | ₹5.38 |
| Diluted Shares | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr |
| Profit Or Loss Of Associates | ₹1 Cr ↑ Recovery | (₹1 Cr) ↓ Decline | ₹0.39 Cr -66.9% | ₹1 Cr ↑ Recovery | (₹0.18 Cr) -157.1% | (₹0.07 Cr) ↓ Decline | ₹0.51 Cr -22.7% | ₹0.66 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Thyrocare Technologies Limited has informed the Exchange about Earnings Call Transcript held on July 23, 2026
Thyrocare Technologies Limited has informed the Exchange regarding submission of machine-readable document of earlier submitted results of the Company for the quarter ended on June 30, 2026
Thyrocare Technologies Limited has informed the Exchange about Copy of Newspaper Publication of unaudited financial results for the quarter ended June 30, 2026
Please find attached herewith Link of Audio Recording for Investor Call held on July 23, 2026
Please refer the enclosed intimation regarding the in-principle approval of the Board of Directors of the Company for evaluation of the proposed restructuring of the radiology business undertaking of ...
Thyrocare Technologies Limited has informed the Exchange regarding re-appointment of M/s. Ernst & Young LLP as Internal Auditor of the Company.
Thyrocare Technologies Limited has informed the Exchange about Investor Presentation
Thyrocare Technologies Limited has informed the Exchange regarding a press release dated July 23, 2026 on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter e...
Outcome of the Board Meeting held on July 23, 2026
Thyrocare Technologies Limited has informed the Exchange about Schedule of meet
Thyrocare Technologies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026
Thyrocare Technologies Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on June 30, 2026. Further, the company has submitted the Exchange a copy of Srutinizers re...
Docon Technologies Private Ltd has submitted to the Exchange a copy of disclosure under Regulations, 31(1) and 31(2) of SEBI ( SAST) Regulations, 2011.
Please find attached herewith copies of Newspaper Publications published on June 05, 2026, in Business Standard (English) and Navshakti (Marathi)
Please find enclosed herewith copies of Newspaper advertisement published on May 25, 2026 in Business Standard (English) and Pratahkal (Marathi).